How India Exports Bambuterol to the World

As of March 2026, Bambuterol does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. This absence suggests that Bambuterol is not currently approved for marketing in the United States. Consequently, there are no recent approvals, import alerts, or established regulatory pathways for this drug in the U.S. market. The limited number of Indian exporters and the primary export destinations being Myanmar and Afghanistan further indicate that Bambuterol's market presence is predominantly outside the United States.

In the European Union, Bambuterol has been authorized through national procedures in several Member States. The European Medicines Agency (EMA) maintains a list of nationally authorized medicinal products, including Bambuterol, as of July 2023. (ema.europa.eu) This indicates that Bambuterol is recognized within the EU, subject to each Member State's regulatory requirements. In the United Kingdom, post-Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of medicinal products. While specific information on Bambuterol's status in the UK is not readily available, it is likely subject to similar national authorization procedures. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for the production and marketing of medicinal products within these regions.

Bambuterol is not listed in the World Health Organization's (WHO) Model List of Essential Medicines, which serves as a guide for the most important medications needed in a basic health system. Additionally, there is no evidence of Bambuterol being included in the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, Bambuterol's monographs are not found in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP). This absence suggests a lack of standardized quality specifications for Bambuterol in these international references.

In India, Bambuterol is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. As of March 2026, Bambuterol is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it does not have a government-mandated ceiling price. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating the export process.

Bambuterol's primary patents have expired, allowing for generic competition in various markets. The presence of multiple exporters from India indicates that generic versions are being produced and distributed. However, the limited number of destination countries suggests that market penetration remains relatively low, potentially due to regulatory barriers or limited demand.

In July 2023, the European Medicines Agency (EMA) published a list of nationally authorized medicinal products, including Bambuterol, reflecting its recognition in several EU Member States. (ema.europa.eu) This development underscores the ongoing regulatory acceptance of Bambuterol within the EU.

In November 2025, the UK's Food Standards Agency (FSA) implemented the Genetic Technology (Precision Breeding) Regulations 2025, allowing businesses to apply for Precision Bred Organism (PBO) food and feed marketing authorizations. (food.gov.uk) While not directly related to Bambuterol, this regulatory change indicates a broader trend towards accommodating innovative products within the UK's regulatory framework.

These developments highlight the dynamic nature of the pharmaceutical regulatory landscape, emphasizing the importance of staying informed about changes that may impact the production, export, and marketing of medicinal products like Bambuterol.

Bambuterol, a bronchodilator used in the management of asthma, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted the supply of petrochemical feedstocks essential for API synthesis, leading to production cutbacks and force majeure declarations across the pharmaceutical industry. Such disruptions underscore the risks associated with concentrated sourcing of critical raw materials.

Our proprietary trade data indicates that the top five exporters of Bambuterol from India account for 51.4% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 51.4%. This high supplier concentration poses a significant single-source risk, as any operational or compliance issues within these key suppliers could disrupt the entire supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce reliance on imports. However, the effectiveness of this initiative in diversifying the supplier base for Bambuterol remains to be fully realized.

The pharmaceutical supply chain is highly susceptible to geopolitical events. The recent conflict in Iran has led to the effective closure of the Strait of Hormuz, a critical chokepoint through which approximately 20% of global oil passes. This disruption has halted oil tanker movements and affected the wider global supply chain, including pharmaceuticals from India. Additionally, instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa’s Cape of Good Hope, adding significant delays and costs.

These disruptions have led to increased transportation costs and extended lead times for pharmaceutical products, including Bambuterol. The FDA has acknowledged such supply chain challenges, emphasizing the need for proactive measures to prevent and mitigate shortages of critical drugs.

• Diversify Supplier Base: Engage with multiple API manufacturers across different regions to reduce dependency on a single source.

• Strengthen Domestic Production: Leverage government incentives like the PLI scheme to enhance local manufacturing capabilities for both APIs and KSMs.

• Enhance Supply Chain Visibility: Implement advanced tracking systems to monitor the movement of raw materials and finished products, enabling swift responses to disruptions.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical events on transportation.

• Collaborate with Regulatory Bodies: Work closely with agencies such as the FDA and EMA to stay informed about potential shortages and regulatory changes, ensuring compliance and preparedness.

RISK_LEVEL: HIGH